NCT00027040

Brief Summary

The purpose of this study is to compare pictures of the brain of HIV-infected people with memory problems before and after treatment with selegiline. Selegiline is the study drug received through A5090. HIV patients generally develop memory problems late in the disease. This will be examined using noninvasive proton magnetic resonance spectroscopy (1H-MRS). The effect of the drug selegiline on memory problems also will be examined.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
90

participants targeted

Target at P50-P75 for not_applicable

Geographic Reach
1 country

12 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 16, 2001

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 19, 2001

Completed
3.5 years until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2005

Completed
Last Updated

January 16, 2015

Status Verified

October 1, 2012

First QC Date

November 16, 2001

Last Update Submit

January 15, 2015

Conditions

Keywords

AIDS Dementia ComplexSelegilineOxidative StressCognitionNeuroprotective AgentsBrain InjuriesMagnetic Resonance SpectroscopyProtons

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients may be eligible for this study if they:
  • Are enrolled in ACTG protocol A5090.

You may not qualify if:

  • Patients will not be eligible for this study if they have:
  • Claustrophobia (unless sedation with lorazepam or zolpidem allows for safe performance of the MRS).
  • Metallic implants/medical devices (e.g., skull implants or cardiac devices).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (12)

UCLA CARE Ctr

Los Angeles, California, 90095, United States

Location

Univ of California, San Diego

San Diego, California, 92103, United States

Location

Stanford University

Stanford, California, 94305-5107, United States

Location

Johns Hopkins Hosp

Baltimore, Maryland, 21287, United States

Location

Mount Sinai Med Ctr

New York, New York, 10029, United States

Location

Columbia Presbyterian Med Ctr

New York, New York, 10032, United States

Location

Univ of Rochester Medical Center

Rochester, New York, 14642, United States

Location

Univ of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

Location

Rhode Island Hosp

Providence, Rhode Island, 02906, United States

Location

Stanley Street Treatment and Resource

Providence, Rhode Island, 02906, United States

Location

The Miriam Hosp

Providence, Rhode Island, 02906, United States

Location

Univ of Washington

Seattle, Washington, 98104, United States

Location

Related Publications (1)

  • Schifitto G, Yiannoutsos CT, Ernst T, Navia BA, Nath A, Sacktor N, Anderson C, Marra CM, Clifford DB; ACTG 5114 Team. Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology. 2009 Dec 8;73(23):1975-81. doi: 10.1212/WNL.0b013e3181c51a48. Epub 2009 Nov 4.

MeSH Terms

Conditions

Cognitive DysfunctionHIV InfectionsAIDS Dementia ComplexBrain Injuries

Interventions

Selegiline

Condition Hierarchy (Ancestors)

Cognition DisordersNeurocognitive DisordersMental DisordersBlood-Borne InfectionsCommunicable DiseasesInfectionsSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesCraniocerebral TraumaTrauma, Nervous SystemWounds and Injuries

Intervention Hierarchy (Ancestors)

PhenethylaminesEthylaminesAminesOrganic Chemicals

Study Officials

  • Giovanni Schifitto

    STUDY CHAIR
  • Bradford Navia

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
not applicable
Purpose
TREATMENT
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 16, 2001

First Posted

November 19, 2001

Study Completion

June 1, 2005

Last Updated

January 16, 2015

Record last verified: 2012-10

Locations